NervGen Pharma Corp (NGEN) — Cash Flow-to-Debt Ratio
NervGen Pharma Corp (NGEN) has a Cash Flow-to-Debt Ratio of -0.33x as of September 2025, meaning its operating cash flow of CA$-5.32 Million could theoretically repay 0% of its total liabilities (CA$16.02 Million) in one year. See NervGen Pharma Corp short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
NervGen Pharma Corp Cash Flow-to-Debt Ratio (2017–2024)
Historical debt coverage capacity for NervGen Pharma Corp across 8 annual periods. Also explore net asset momentum of NervGen Pharma Corp to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for NervGen Pharma Corp (2017–2024)
Year-by-year debt coverage analysis for NervGen Pharma Corp. For market capitalisation and broader financial context, see NervGen Pharma Corp market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (CAD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.00x | CA$-16.84 Million | CA$16.91 Million | ▼ -34.4% |
| 2023 | -0.74x | CA$-11.30 Million | CA$15.25 Million | ▲ +56.6% |
| 2022 | -1.71x | CA$-17.78 Million | CA$10.41 Million | ▲ +77.7% |
| 2021 | -7.67x | CA$-8.27 Million | CA$1.08 Million | ▲ +8.2% |
| 2020 | -8.35x | CA$-6.31 Million | CA$755.07K | ▲ +4.7% |
| 2019 | -8.76x | CA$-8.09 Million | CA$923.95K | ▼ -391.1% |
| 2018 | -1.78x | CA$-1.04 Million | CA$583.11K | ▲ +83.7% |
| 2017 | -10.94x | CA$-1.04 Million | CA$95.06K | — |